ENGINEERED DNASE ENZYMES AND USE IN THERAPY

ABSTRACT

The present invention provides engineered DNase proteins (including DNase 1-like 3 and DNase 1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.

FIG. 1A